| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Jiangsu Sihuan Bioengineering Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥2.45 |
| 52 Week High | CN¥4.57 |
| 52 Week Low | CN¥1.72 |
| Beta | 0.54 |
| 1 Month Change | 15.02% |
| 3 Month Change | 26.29% |
| 1 Year Change | -12.19% |
| 3 Year Change | -37.97% |
| 5 Year Change | -29.19% |
| Change since IPO | -70.69% |
Recent News & Updates
Recent updates
Shareholder Returns
| 518 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -12.5% | -5.5% | -1.5% |
| 1Y | -12.2% | -17.5% | -11.3% |
Return vs Industry: 000518 exceeded the CN Biotechs industry which returned -17.5% over the past year.
Return vs Market: 000518 matched the CN Market which returned -11.3% over the past year.
Price Volatility
| 518 volatility | |
|---|---|
| 518 Average Weekly Movement | 9.1% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in CN Market | 10.8% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 000518 has not had significant price volatility in the past 3 months.
Volatility Over Time: 000518's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 250 | Yu Guo | www.000518shsw.com/shsw |
Jiangsu Sihuan Bioengineering Co., Ltd. engages in the pharmaceutical business in China. It offers delusen, an anti-tumor biotherapeutic drug for the treatment of kidney cancer, malignant melanoma, and cancerous chest and abdominal mass; Xinde Lusheng; Xin Lisheng; and Ring BO. It also engages in breeding and sales of flowers and seedlings; and landscaping projects.
Jiangsu Sihuan Bioengineering Co., Ltd Fundamentals Summary
| 518 fundamental statistics | |
|---|---|
| Market cap | CN¥2.52b |
| Earnings (TTM) | -CN¥59.28m |
| Revenue (TTM) | CN¥234.80m |
10.7x
P/S Ratio-42.6x
P/E RatioIs 518 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 518 income statement (TTM) | |
|---|---|
| Revenue | CN¥234.80m |
| Cost of Revenue | CN¥69.16m |
| Gross Profit | CN¥165.64m |
| Other Expenses | CN¥224.92m |
| Earnings | -CN¥59.28m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.058 |
| Gross Margin | 70.54% |
| Net Profit Margin | -25.25% |
| Debt/Equity Ratio | 4.2% |
How did 518 perform over the long term?
See historical performance and comparison